1. Home
  2. HRMY vs VVX Comparison

HRMY vs VVX Comparison

Compare HRMY & VVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HRMY
  • VVX
  • Stock Information
  • Founded
  • HRMY 2017
  • VVX 2014
  • Country
  • HRMY United States
  • VVX United States
  • Employees
  • HRMY N/A
  • VVX 16100
  • Industry
  • HRMY Biotechnology: Pharmaceutical Preparations
  • VVX Diversified Commercial Services
  • Sector
  • HRMY Health Care
  • VVX Consumer Discretionary
  • Exchange
  • HRMY Nasdaq
  • VVX Nasdaq
  • Market Cap
  • HRMY 1.8B
  • VVX 1.6B
  • IPO Year
  • HRMY 2020
  • VVX 2014
  • Fundamental
  • Price
  • HRMY $34.00
  • VVX $49.21
  • Analyst Decision
  • HRMY Strong Buy
  • VVX Buy
  • Analyst Count
  • HRMY 9
  • VVX 9
  • Target Price
  • HRMY $54.44
  • VVX $64.11
  • AVG Volume (30 Days)
  • HRMY 642.5K
  • VVX 251.1K
  • Earning Date
  • HRMY 08-05-2025
  • VVX 08-04-2025
  • Dividend Yield
  • HRMY N/A
  • VVX N/A
  • EPS Growth
  • HRMY 13.13
  • VVX N/A
  • EPS
  • HRMY 2.62
  • VVX 1.29
  • Revenue
  • HRMY $744,852,000.00
  • VVX $4,327,514,000.00
  • Revenue This Year
  • HRMY $20.10
  • VVX $4.02
  • Revenue Next Year
  • HRMY $18.01
  • VVX $4.80
  • P/E Ratio
  • HRMY $13.10
  • VVX $38.10
  • Revenue Growth
  • HRMY 20.62
  • VVX 7.38
  • 52 Week Low
  • HRMY $26.47
  • VVX $41.08
  • 52 Week High
  • HRMY $41.61
  • VVX $69.75
  • Technical
  • Relative Strength Index (RSI)
  • HRMY 58.91
  • VVX 58.54
  • Support Level
  • HRMY $31.70
  • VVX $48.84
  • Resistance Level
  • HRMY $35.08
  • VVX $50.29
  • Average True Range (ATR)
  • HRMY 0.95
  • VVX 1.22
  • MACD
  • HRMY 0.27
  • VVX 0.26
  • Stochastic Oscillator
  • HRMY 71.80
  • VVX 76.55

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About VVX V2X Inc.

V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.

Share on Social Networks: